Melinta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to introducing new antibiotics that meet the ever-present challenge posed by dangerous and increasingly resistant bacteria. The company received FDA approval of our lead antibiotic, Baxdela (delafloxacin), for the treatment of adults with serious skin infections known as acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is studying Baxdela in a Phase 3 clinical program in serious community-acquired bacterial pneumonia (CABP) and may develop additional indications such as complicated urinary tract infections (cUTI). Melinta is also developing, through the application of Nobel Prize-winning science and a proprietary drug discovery platform, novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and Escherichia coli), which cause the majority of life-threatening hospital infections.
Melinta Therapeutics is privately held with offices in New Haven, CT and Lincolnshire, IL.